Olivia Goldhill

STAT surveyed 100 hospitals across 50 states about changes in maternal care after overturning of Roe v. Wade. Only six agreed to speak.

FDA urged to probe claims of underreported adverse events in Lykos Therapeutics trials of psychedelic therapy for PTSD.

As Lykos Therapeutics seeks a landmark approval of psychedelic therapy for PTSD, it will face scrutiny from an FDA advisory panel next week.

FDA advisers weigh the first use of psychedelic therapy for post-traumatic stress disorder, review safety and efficacy data from MDMA trials.

The psychedelics company oversaw a pattern of lapses during its clinical trials, according to former employees who spoke with STAT.

Despite an advisory panel’s strong criticisms of MDMA, the FDA’s favorable view of psychedelics suggests an approval is quite possible.

The FDA said it’s investigating Lykos studies of MDMA treatment for PTSD. Key people involved in misconduct claims have yet to be contacted.

Shifting from topic to topic, with few connections, is one of several disjointed and occasionally incoherent verbal habits that seem to have increased in Trump’s speech.

Existing therapies don't work well for many people with PTSD, and no new drug for the disorder has been approved in more than two decades.

MDMA therapy is facing an imminent FDA decision. Here’s what you need to know